| Type 2 Diabetes Mellitus |
1 |
1 |
| Hypertension |
0 |
0.99 |
| Blood |
0 |
0.75 |
| Genomic Medicine |
0 |
0.52 |
| ACE Inhibitor |
0 |
0.98 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.41 |
| Arrhythmia |
0 |
0.29 |
| Antihypertensive Agents |
0 |
0.96 |
| Diuretics |
0 |
0.2 |
| Beta Blockers |
0 |
0.97 |
| Clinical Guidelines |
0 |
0.17 |
| Guidelines for Hypertension |
0 |
0.17 |
| Osteoarthritis |
0 |
0.16 |
| Calcium Channel Blockers |
0 |
0.14 |
| Meta-Analysis |
0 |
0.14 |
| Cardiovascular Risk Management |
0 |
0.13 |
| Calcium |
0 |
0.1 |
| Cerebrovascular Accident |
0 |
0.1 |
| Genetics |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Heart |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.03 |
| Clinical Pharmacology |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Kidney |
0 |
0.03 |
| Kidney, Ureter, and Bladder |
0 |
0.03 |
| Prediabetes |
0 |
0.03 |
| Renin-Angiotensin System |
0 |
0.95 |
| Statistics |
0 |
0.03 |
| UK Site Content |
0 |
0.03 |